Rakici 2014.

Methods	Randomised, controlled trial Dates the study was conducted: from January 2010 to December 2011 Funding sources and potential conflicts of interest: no funding reported. Authors declare no conflicts of interest Definition of compliance: Non‐compliance was defined as participants who were reluctant to take the drugs due to nausea, diarrhoea, a bitter taste in the mouth, an allergic reaction and feeling ill
Participants	umber and type of participants: 514 H.pylori‐positive were enrolled in the study Participants were randomised into to 3 different treatment groups: 14‐day STT, 10‐day SEQ and a modified triple therapy (with moxifloxacin and metronidazole). For our review purpose, only data related to STT and SEQ are relevant. Country: Turkey Number of participants randomised: 514 Number of participants in the 7‐day STT arm: 171 Number of participants in the 10‐day SEQ arm: 172 Average age (range) of the population in years, reported by treatment group: 14‐day STT: 46.3 (18 – 75) 10‐day SEQ: 46.9 (18 – 79) Medical condition at baseline reported as number of participants (%) in the 14‐day STT regimen/10‐day SEQ regimen: Normal: 13 (7.6)/1 (0.6) Gastritis: 137 (80.1)/145 (84.3) Peptic ulcer: 21 (12.3)/26 (15.1) Sex (M/F) per treatment group: 7‐day STT: 76/95 10‐day SEQ: 72/100 H. pylori diagnostic methods in both treatment arms: histological examination and stool antigen tests
Interventions	Participants randomised to the SEQ group were administered metronidazole Name, dose timing of antibiotics in 14‐day STT: lansoprazole 30 mg twice a day + clarithromycin 500 mg twice a day + amoxicillin 1 g twice a day (during 7 days) Length of STT (days): 14 Name, dose timing of antibiotics in 10‐day SEQ: lansoprazole 30 mg twice a day + amoxicillin 1 g twice a day (during 5 days) and lansoprazole 30 mg twice a day + clarithromycin 500 mg twice a day + metronidazole 500 mg twice a day (during 5 days) (Total: 10 days) Sensitivity test (yes/no) to antibiotics before/after treatment: not performed Method of assessment of H. pylori status after treatment: stool antigen testing Time for assessment of H. pylori status after treatment: 4 ‐ 6 weeks
Outcomes	The study flow chart showed that in the 14‐day STT arm there were 2 losses, and in the 10‐day SEQ there were 2 losses ITT eradication rate (%) by treatment group: 14‐day STT: 144/171 (84.2) 10‐day SEQ: 146/172 (84.9) PP eradication rate (%) by treatment group: 14‐day STT: 144/169 (85.2) 10‐day SEQ: 146/170 (85.8) Metronidazole resistance (%) before treatment, SEQ ITT/PP: not reported Metronidazole resistance (%) before treatment, STT ITT/PP: not reported Clarithromycin resistance (%) before treatment, SEQ ITT/PP: not reported Clarithromycin resistance (%) before treatment, STT ITT/PP: not reported Compliance (%) in ITT sample SEQ/STT: not reported Adherence > 90% (n, (%)) in ITT sample: not reported Incidence n (%) of AEs, by treatment group: not reported Incidence (n, %) serious AEs, SEQ / STT: not reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were reported to be randomised but method of randomisation given
Allocation concealment (selection bias)	Unclear risk	Concealment of the sequence was not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcomes were clearly reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported
Publication format	Low risk	Full article